Canntab Therapeutics Ltd
CNSX:PILL
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Canntab Therapeutics Ltd
PP&E Gross
Canntab Therapeutics Ltd
PP&E Gross Peer Comparison
Canntab Therapeutics Ltd
Glance View
Canntab Therapeutics Ltd. is a biopharmaceutical company. The company is headquartered in Toronto, Ontario. The company went IPO on 2011-04-21. The firm is focused on the manufacturing and distribution of a suite of hard pill cannabinoid formulations in multiple doses and timed-release combinations. The firm operates in one reportable operating, being engaged in the medical marijuana business. All property and equipment, right-of-use assets and intangible assets are located in Canada. Its hard pill cannabinoid formulations provide doctors, patients and consumers with medical grade solutions. Its products include INSTANT RELEASE - (IR Tablet), EXTENDED-RELEASE - (XR Tablet), and ORAL DISSOLVING - O.D. Tablet. The company holds cannabis standard processing and sales for medical purposes license, a cannabis research license, and an industrial hemp license from health Canada.
See Also
What is Canntab Therapeutics Ltd's PP&E Gross?
PP&E Gross
1.1m
CAD
Based on the financial report for May 31, 2022, Canntab Therapeutics Ltd's PP&E Gross amounts to 1.1m CAD.
What is Canntab Therapeutics Ltd's PP&E Gross growth rate?
PP&E Gross CAGR 1Y
-58%
Over the last year, the PP&E Gross growth was -58%.
